InnoCan Pharma (FRA:IP40) Risk Assessment


FRA:IP40 InnoCan Pharma Corp FRA:IP40
54 GF Score
Price €1.92
GF Value €9.36
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of InnoCan Pharma is: High Risk: High uncertainty.

InnoCan Pharma  (FRA:IP40) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

InnoCan Pharma Risk Assessment Related Terms

FRA:IP40 vs PG, CL, KVUE: Risk Assessment Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma Risk Assessment vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Risk Assessment falls into.


FRA:IP40
54GF Score
InnoCan Pharma Corp FRA:IP40
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.92 is trading 79.5% below its estimated GF Value™ of €9.36. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Risk Assessment:
  • GF Value™: €9.36 vs. price of €1.92 (79.5% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
54GF Score

Get the complete analysis for FRA:IP40

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.92
Price
€9.36
GF Value